Can the diltiazem (Cardizem) infusion be continued while administering intravenous digoxin?

Can You Keep the Diltiazem Drip Going While Giving IV Digoxin?

Yes, you can safely continue the diltiazem infusion while administering IV digoxin, and this combination is actually recommended for enhanced rate control in atrial fibrillation when monotherapy fails. 12

Evidence-Based Rationale

The 2015 ACC/AHA/HRS guidelines explicitly list both diltiazem and digoxin as acceptable rate control agents for supraventricular tachycardia, with no contraindication to their concurrent use 1. In fact, the 2014 AATS guidelines specifically recommend combination therapy: "Combination use of AV nodal blocking agents, such as β-blockers, non-dihydropyridine calcium channel antagonists (e.g., diltiazem), or digoxin, can be useful to control heart rates when a single agent fails to control rates" 2.

Why Combination Therapy Works

• Complementary mechanisms: Diltiazem blocks L-type calcium channels in nodal tissue with onset in 2-7 minutes 33, while digoxin provides vagomimetic effects with slower onset (30 minutes to 2 hours) 33
• Enhanced efficacy: The AFFIRM trial showed diltiazem controlled rest and exercise heart rate in ~60% of patients alone, but 66-79% when combined with digoxin 333
• Additive AV nodal depression: A 1982 electrophysiology study demonstrated that diltiazem and digoxin have additive depressant effects on SA and AV node function without significant adverse effects 4

Clinical Evidence Supporting Concurrent Use

The strongest recent evidence comes from a 2001 prospective randomized trial 5 comparing IV diltiazem alone versus IV diltiazem plus digoxin combination:

• Both groups achieved successful rate control at 12 hours
• Combination therapy resulted in fewer episodes of loss of rate control (14 vs 39 episodes, p=0.05)
• Fewer episodes per patient (2.0±1.0 vs 3.5±1.9, p=0.04)
• Time to rate control was faster with combination (15±16 vs 22±22 minutes)

Critical Safety Considerations

Monitor Closely For:

1. Bradycardia: Both drugs slow AV conduction—watch for excessive heart rate reduction, especially when AF terminates
2. Hypotension: Diltiazem causes vasodilation; digoxin may help maintain blood pressure in this setting 3
3. Digoxin toxicity risk increases with:
   • Hypokalemia, hypomagnesemia, hypercalcemia
   • Renal dysfunction (digoxin accumulates)
   • Verapamil coadministration (but diltiazem interaction is less pronounced) 33

Drug Interaction Details from FDA Label

The Cardizem FDA label states: "Administration of CARDIZEM with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%" 6. The label recommends monitoring digoxin levels when initiating, adjusting, and discontinuing diltiazem therapy to avoid over- or under-digitalization 6.

Practical Algorithm

When to use combination therapy:

1. Start with diltiazem drip alone (0.25 mg/kg bolus, then 5-15 mg/h infusion) 12
2. If rate control inadequate after 30-60 minutes (HR remains >100-110 bpm)
3. Add digoxin (0.25-0.5 mg IV bolus, can repeat 0.25 mg every 2-6 hours up to 1.5 mg/24h) 1
4. Continue both agents with close monitoring

Avoid combination if:

• Suspected accessory pathway (WPW syndrome) 13
• Severe hypotension (SBP <90 mmHg)
• Advanced AV block (>1st degree) without pacemaker 1
• Decompensated heart failure with reduced ejection fraction (use caution) 3

Common Pitfall to Avoid

Do NOT assume you must stop diltiazem before giving digoxin. A 1996 case report 7 described a fatality with diltiazem in a patient with hyperkalemia and suspected digoxin toxicity—but this was a specific high-risk scenario, not a contraindication to the combination itself. The key is recognizing when NOT to use either drug (accessory pathways, severe hypotension, advanced heart block), not avoiding their combination in appropriate patients.

Bottom line: Continue the diltiazem drip and add digoxin when monotherapy fails—this is guideline-supported, evidence-based practice for refractory rate control. 125